TG Therapeutics shares are advancing steadily. What’s pushing TGTX stock higher?
TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in myasthenia gravis, with 82% of subjects hitting a minimal clinically important difference in MG-ADL and a mean improvement of over four points. Management also said it plans to start a Phase 2 trial enrolling about 120 patients, aiming to pair rapid symptom control with longer-term disease modification.With markets open, the broader tone is supportive for risk: the Nasdaq-100 is up 2.22% and the Russell 2000 is up 1.48%, even though market breadth is mixed (an advance/decline ratio of 0.8). That backdrop matters because TGTX is outperforming on a day when its sector is a drag, which usually points back to company-specific news flow.Critical Price Levels To Watch For TGTXThe longer-term trend remains firmly bullish: the stock is trading 23.4% above its 20-day SMA ($42.46) and 56.3% above its 200-day SMA ($33.53), and it's still benefiting from the golden cross that formed in April. The trade-off is that this kind of extension can amplify pullbacks if momentum cools, especially near prior breakout areas.RSI is the cleaner momentum lens right now, and at 81.03 it's in overbought territory—basically a "stretched" reading that often shows buyers have been aggressive and the stock may need to pause or digest. If you want a secondary check, MACD remains in a bullish posture (above its signal line), which typically supports "buy-the-dip" behavior until that relationship flips.
